pharma news today glp-1 obesity drugs Consumer group presses U.S. to authorize generic GLP-1s GLP-1 Therapies Drive Indian Pharma

This is a non-trivial point: it would imply that the entire downstream literature has been studying a synthetic mimic of an incompletely characterized native species

El Nutri-Score no mide eficacia ni calidad de los ingredientes activos

Not necessarily IgG4-RD does not cause most headache cases

Doseresponse effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP- 1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial

Neuroinflammation 14 (1), 179179

doi: 10.1016/j.bbi.2022.02.003 196 OliveiraTGChanRBBravoFVMirandaASilvaRRZhouBet al